0
0

Chapter 63. Treatment of Child and Adolescent Disorders

Karen Dineen Wagner, M.D., Ph.D.; Steven R. Pliszka, M.D.
DOI: 10.1176/appi.books.9781585623860.435382

Sections

Excerpt

This chapter focuses on the psychopharmacology of psychiatric disorders in children and adolescents. However, nonpharmacological treatment interventions are also an important component of a child's psychiatric care. Individual psychotherapy, group therapy, and family therapy may improve clinical outcome. Working closely with school personnel is another ingredient in the treatment of a child with a psychiatric disorder. Case management for the child and support for the family are other facets of treatment for children.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Table Reference Number
TABLE 63–1. Clinical use of antidepressants in children and adolescents
Table Reference Number
TABLE 63–2. Clinical use of atypical antipsychotics in children and adolescents
Table Reference Number
TABLE 63–3. Clinical use of mood stabilizers in children and adolescents
Table Reference Number
TABLE 63–4. Clinical use of psychostimulants in children and adolescents

References

Abbott Laboratories: Multicenter Controlled Trial of Divalproex ER for Pediatric Bipolar I Disorder. Abbott Park, IL, Abbott Labs, 2007. Available at: http://www.clinicalstudyresults.org. Accessed May 24, 2007.
 
Abikoff H, McGough J, Vitiello B et al: Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry 44:418–427, 2005
[PubMed]
 
Acosta MT, Castellanos FX: Use of the "inverse neuroleptic" metoclopramide in Tourette syndrome: an open case series. J Child Adolesc Psychopharmacol 14:123–128, 2004
[PubMed]
 
Alessi N, Bos T: Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder. Am J Psychiatry 148:1605–1606, 1991
[PubMed]
 
Allen AJ, Kurlan RM, Gilbert DL, et al: Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 65:1941–1949, 2005
[PubMed]
 
Aman MG, Kern RA: Review of fenfluramine in the treatment of the developmental disabilities. J Am Acad Child Adolesc Psychiatry 28:549–565, 1989
[PubMed]
 
Aman MG, De Smedt G, Derivan A, et al: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337–1346, 2002
[PubMed]
 
Aman MG, Binder C, Turgay A: Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243–254, 2004
[PubMed]
 
Ambrosini PJ, Bianchi MD, Metz C, et al: Evaluating clinical response of open nortriptyline pharmacotherapy in adolescent major depression. J Child Adolesc Psychopharmacol 4:233–244, 1994
 
American Academy of Child and Adolescent Psychiatry: Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 37 (10 suppl):27S–45S, 1998
 
American Academy of Child and Adolescent Psychiatry: Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 40 (7 suppl):4S–23S, 2001
 
American Academy of Child and Adolescent Psychiatry: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894–921, 2007
 
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596–601, 2004
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington, DC, American Psychiatric Association, 1987
 
American Psychiatric Association: Diagnostic and Statistical Manual for Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
 
Anderson JC, Williams S, McGee R, et al: DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population. Arch Gen Psychiatry 44:69–76, 1987
[PubMed]
 
Anderson LT, Campbell M, Grega DM, et al: Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141:1195–1202, 1984
[PubMed]
 
Anderson LT, Campbell M, Adams P, et al: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227–239, 1989
[PubMed]
 
Armenteros JL, Adams PB, Campbell M, et al: Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. Psychopharmacol Bull 31:363–369, 1995
[PubMed]
 
Armenteros JL, Lewis JE, Davalos M: Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 46:558–565, 2007
[PubMed]
 
Arnold LE: Methylphenidate vs amphetamine: comparative review. J Attention Disord 3:200–211, 2000
 
Asbahr FR, Castillo AR, Montenegro L, et al: Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 44:1128–1136, 2005
[PubMed]
 
August GJ, Raz N, Papanicolaou AC, et al: Fenfluramine treatment in infantile autism. Neurochemical, electrophysiological, and behavioral effects. J Nerv Ment Dis 172:604–612, 1984
[PubMed]
 
August GJ, Raz N, Baird TD: Effects of fenfluramine on behavioral, cognitive, and affective disturbances in autistic children. J Autism Dev Disord 15:97–107, 1985
[PubMed]
 
Ballenger JC, Carek DJ, Steele JJ, et al: Three cases of panic disorder with agoraphobia in children. Am J Psychiatry 146:922–924, 1989
[PubMed]
 
Barbaresi WJ, Katusic SK, Colligan RC, et al: How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med 156:217–224, 2002
[PubMed]
 
Barbey JT, Roose SP: SSRI safety in overdose. J Clin Psychiatry 59 (suppl 15):42–48, 1998
 
Barkley RA: Attention Deficit Hyperactivity Disorder: A Clinical Handbook, 3rd Edition. New York, Guilford, 2005
 
Barnett M, Cohen S: Ziprasidone's metabolic effects in pediatric bipolar disorder. Presented at the 51st annual meeting of American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19–24, 2004
 
Barrett RP, Feinstein C, Hole WT: Effects of naloxone and naltrexone on self-injury: a double-blind, placebo controlled analysis. Am J Ment Retard 93:644–651, 1989
[PubMed]
 
Barrickman L, Noyes R, Kuperman S, et al: Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762–767, 1991
[PubMed]
 
Barrickman LL, Perry PJ, Allen AJ, et al: Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:649–657, 1995
[PubMed]
 
Barthelemy C, Bruneau N, Jouve J, et al: Urinary dopamine metabolites as indicators of the responsiveness to fenfluramine treatment in children with autistic behavior. J Autism Dev Disord 19:241–254, 1989
[PubMed]
 
Barzman DH, DelBello MP, Kowatch RA, et al: The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolescent Psychopharmacol 14:593–600, 2004
[PubMed]
 
Barzman DH, DelBello MP, Adler CM, et al: The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J Child Adolesc Psychopharmacol 16:665–670, 2006
[PubMed]
 
Beeghly JH, Kuperman S, Perry PJ, et al: Fenfluramine treatment of autism: relationship of treatment response to blood levels of fenfluramine and norfenfluramine. J Autism Dev Disord 17:541–548, 1987
[PubMed]
 
Beisler JM, Tsai LY, Stiefel B: The effects of fenfluramine on communication skills in autistic children. J Autism Dev Disord 16:227–233, 1986
[PubMed]
 
Belsito KM, Law PA, Kirk KS, et al: Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 31:175–181, 2001
[PubMed]
 
Berard R, Fond R, Carpenter DJ, et al: An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 16:59–75, 2006
[PubMed]
 
Berney T, Kolvin I, Bhate SR, et al: School phobia: a therapeutic trial with clomipramine and short-term outcome. Br J Psychiatry 138:110–118, 1981
[PubMed]
 
Bernstein GA, Garfinkel BD, Borchardt CM: Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry 29:773–781, 1990
[PubMed]
 
Bernstein GA, Borchardt CM, Perwien AR: Anxiety disorders in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 35:1110–1119, 1996
[PubMed]
 
Bernstein GA, Borchardt CM, Perwien AR, et al: Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry 39:276–283, 2000
[PubMed]
 
Bernstein GA, Hektner JM, Borchardt CM, et al: Treatment of school refusal: one-year follow-up. J Am Acad Child Adolesc Psychiatry 40:206–213, 2001
[PubMed]
 
Biederman J: Comparative efficacy of atypical antipsychotics for pediatric bipolar disorder. Poster presented at the 158th annual meeting of the American Psychiatric Association, Atlanta, GA, May 21–26, 2005
 
Biederman J, Faraone SV, Marrs A, et al: Panic disorder and agoraphobia in consecutively referred children and adolescents. J Am Acad Child Adolesc Psychiatry 36:214–223, 1997
[PubMed]
 
Biederman J, Lopez FA, Boellner SW, et al: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110:258–266, 2002
[PubMed]
 
Biederman J, McDonnell MA, Wozniak J, et al: Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr 10:141–148, 2005a
 
Biederman J, Mick E, Hammerness P, et al: Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 58:589–594, 2005b
 
Biederman J, Mick E, Wozniak J, et al: An Open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 15:311–317, 2005c
 
Biederman J, Swanson JM, Wigal SB, et al: Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116:e777–e784, 2005d
 
Biederman J, Mick E, Surman C, et al: A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59:829–835, 2006a
 
Biederman J, Wigal SB, Spencer TJ, et al: A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clin Ther 28:280–293, 2006b
 
Birmaher B, Waterman GS, Ryan ND, et al: Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment resistant" major depression. J Am Acad Child Adolesc Psychiatry 37:527–535, 1998
[PubMed]
 
Birmaher B, Arbelaez C, Brent D: Course and outcome of child and adolescent major depressive disorder. Child Adolesc Psychiatry Clin North Am 11:619–637, 2002
[PubMed]
 
Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 42:415–423, 2003
[PubMed]
 
Birmaher B, Axelson D, Strober M, et al: Clinical course of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 63:175–183, 2006
[PubMed]
 
Bitter I, Czobor P, Dossenbach M, et al: Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). Eur Psychiatry 20:403–408, 2005
[PubMed]
 
Black B, Uhde TW: Elective mutism as a variant of social phobia. J Am Acad Child Adolesc Psychiatry 31:1090–1094, 1992
[PubMed]
 
Black B, Uhde TW: Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 33:1000–1006, 1994
[PubMed]
 
Blair J, Scahill L, State M, et al: Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 44:73–79, 2005
[PubMed]
 
Bouvard MP, Leboyer M, Launay JM, et al: Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res 58:191–201, 1995
[PubMed]
 
Brent DA, Holder D, Kolko D, et al: A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry 54:877–885, 1997
[PubMed]
 
Bridge JA, Iyengar S, Salary CB, et al: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297:1683–1696, 2007
[PubMed]
 
Bruggeman R, van der Linden C, Buitelaar JK, et al: Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 62:50–56, 2001
[PubMed]
 
Budman CL, Gayer A, Lesser M, et al: An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry 62:290–294, 2001
[PubMed]
 
Buitelaar JK, van der Gaag RJ, van der Hoeven J: Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry 59:56–59, 1998
[PubMed]
 
Buitelaar JK, Willemsen-Swinkels SH: Medication treatment in subjects with autistic spectrum disorders. Eur Child Adolesc Psychiatry 9 (suppl 1):I85–I97, 2000
 
Buitelaar JK, Van der Gaag RJ, Cohen-Kettenis P, et al: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities [comment]. J Clin Psychiatry 62:239–248, 2001
[PubMed]
 
Bymaster FP, Katner JS, Nelson DL, et al: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711, 2002
[PubMed]
 
Campbell M, Anderson LT, Meier M, et al: A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640–655, 1978
[PubMed]
 
Campbell M, Anderson LT, Small AM, et al: The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord 12:167–175, 1982
[PubMed]
 
Campbell M, Small AM, Green WH, et al: Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650–656, 1984
[PubMed]
 
Campbell M, Perry R, Polonsky BB, et al: An open study of fenfluramine in hospitalized young autistic children. J Autism Dev Disord 16:495–506, 1986
[PubMed]
 
Campbell M, Adams P, Perry R, et al: Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 24:251–255, 1988a
 
Campbell M, Adams P, Small AM, et al: Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry 27:434–439, 1988b
 
Campbell M, Anderson LT, Small AM, et al: Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 32:1283–1291, 1993
[PubMed]
 
Campbell M, Adams PB, Small AM, et al: Lithium in hospitalized aggressive children with conduct disorder: a double blind and placebo controlled study. J Am Acad Child Adolesc Psychiatry 34:445–453, 1995
[PubMed]
 
Campbell M, Armenteros JL, Malone RP, et al: Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835–843, 1997
[PubMed]
 
Cantwell DP, Swanson J, Connor DF: Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiatry 36:539–544, 1997
[PubMed]
 
Castellanos FX, Giedd JN, Elia J, et al: Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 36:589–596, 1997
[PubMed]
 
Centers for Disease Control and Prevention: Mental health in the United States. Prevalence of diagnosis and medication treatment for attention deficit/hyperactivity disorder—United States 2003. MMWR Morb Mortal Wkly Rep 54:842–847, 2005
 
Chambers WJ, Puig-Antich J, Hirsch M, et al: The assessment of affective disorders in children and adolescents by semistructured interview. Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version. Arch Gen Psychiatry 42:696–702, 1985
[PubMed]
 
Chang K, Saxena K, Howe M, et al: An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 45:298–304, 2006
[PubMed]
 
Chappell PB, Riddle MA, Scahill L, et al: Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 34:1140–1146, 1995b
 
Chavira DA, Stein MB: Combined psychoeducation and treatment with selective serotonin reuptake inhibitors for youth with generalized social anxiety disorder. J Child Adolesc Psychopharmacol 12:47–54, 2002
[PubMed]
 
Charach A, Figueroa M, Chen S, et al: Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 45:415–421, 2006
[PubMed]
 
Childress AC, Krishman S, McGough JJ, et al: Interim analysis of a long-term, open-label, single-arm study of lisdexamfetamine (LDX), an amphetamine prodrug, in children with ADHD. Presented at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, October 27, 2006
 
Clark DB, Birmaher B, Axelson D, et al: Fluoxetine for the treatment of childhood anxiety disorder: open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 44:1263–1270, 2005
[PubMed]
 
Clarke GN, Sack WH, Ben R, et al: English language skills in a group of previously traumatized Khmer adolescent refugees. J Nerv Ment Dis 181:454–456, 1993
[PubMed]
 
Coggins TE, Morisset C, Krasney L, et al: Brief report: does fenfluramine treatment enhance the cognitive and communicative functioning of autistic children? J Autism Dev Disord 18:425–434, 1988
[PubMed]
 
Cohen IL, Campbell M, Posner D, et al: Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 19:665–677, 1980
[PubMed]
 
Comings DE, Himes JA, Comings BG: An epidemiologic study of Tourette's syndrome in a single school district. J Clin Psychiatry 51:463–469, 1990
[PubMed]
 
Compton SN, Grant PJ, Chrisman AK, et al: Sertraline in children and adolescents with social anxiety disorder. J Am Acad Adolesc Psychiatry 40:564–571, 2001
[PubMed]
 
Coniglio SJ, Lewis JD, Lang C, et al: A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr 138:649–655, 2001
[PubMed]
 
Conners CK, Casat CD, Gualtieri CT, et al: Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314–1321, 1996
[PubMed]
 
Connor DF, Ozbayrak KR, Benjamin S, et al: A pilot study of nadolol for overt aggression in developmentally delayed individuals. J Am Acad Child Adolesc Psychiatry 36:826–834, 1997
[PubMed]
 
Connor DF, Fletcher KE, Swanson JM: A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 38:1551–1559, 1999
[PubMed]
 
Connor DF, Barkley RA, Davis HT: A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant disorder or conduct disorder. Clin Pediatr 39:15–25, 2000
[PubMed]
 
Connor DF, Glatt SJ, Lopez ID, et al: Psychopharmacology and aggression, I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 41:253–261, 2002
[PubMed]
 
Cook EH, Rowlett R, Jaselskis C, et al: Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 31:739–745, 1992
[PubMed]
 
Cook EH, Wagner KD, March JS, et al: Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 40:1175–1181, 2001
[PubMed]
 
Copur M, Arpaci B, Demir T, et al: Clinical effectiveness of quetiapine in children and adolescents with Tourette's syndrome: a retrospective case-note survey. Clin Drug Investig 27:123–130, 2007
[PubMed]
 
Corbett B, Khan K, Czapansky-Beilman D, et al: A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism. Clin Pediatr 40:327–331, 2001
[PubMed]
 
Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771–791, 2006
[PubMed]
 
Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414–425, 2004
[PubMed]
 
Correll CU, Penzer JB, Parikh UH, et al: Recognising and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am 15:177–206, 2006
[PubMed]
 
Couturier JL, Nicolson R: A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 12:243–248, 2002
[PubMed]
 
Cummings DD, Singer HS, Krieger M, et al: Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 25:325–332, 2002
[PubMed]
 
Daly JM, Wilens T: The use of tricyclic antidepressants in children and adolescents. Pediatr Clin North Am 45:1123–1135, 1998
[PubMed]
 
D'Amato G: Chlordiazepoxide in management of school phobia. Dis Nerv Syst 23:292–295, 1962
[PubMed]
 
Davanzo PA, McCracken JT: Mood stabilizers in the treatment of juvenile bipolar disorder: advances and controversies. Child Adolesc Psychiatr Clin N Am 9:159–182, 2000
[PubMed]
 
Davies L, Stern JS, Agrawal N, et al: A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol. 21:447–453, 2006
[PubMed]
 
Daviss WB, Bentivoglio P, Racusin R, et al: Bupropion sustained release in adolescents with co morbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 40:307–314, 2001
[PubMed]
 
DelBello MP, Kowatch RA: Pharmacological interventions for bipolar youth: developmental considerations. Dev Psychopathol 18:1231–1246, 2006
[PubMed]
 
DelBello M, Schwiers ML, Rosenberg HL: A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 41:1216–1223, 2002
[PubMed]
 
DelBello MP, Findling RL, Kushner S, et al: A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:539–547, 2005
[PubMed]
 
DelBello MP, Kowatch RA, Adler CM, et al: A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry, 45:305–313, 2006
[PubMed]
 
DeLong GR, Nieman GW: Lithium-induced behavior changes in children with symptoms suggesting manic-depressive illness. Psychopharmacol Bull 19:258–265, 1983
[PubMed]
 
DeVeaugh-Geiss J, Moroz G, Biederman J, et al: Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder—a multicenter trial. J Am Acad Child Adolesc Psychiatry 31:45–49, 1992
[PubMed]
 
Desarkar P, Das A, Sinha VK: Duloxetine for childhood depression with pain and dissociative symptoms. Eur Child Adolesc Psychiatry 15:496–499, 2006
[PubMed]
 
Dion Y, Annable L, Sandor P, et al: Risperidone in the treatment of Tourette syndrome: a double blind, placebo controlled trial. J Clin Psychopharmacol 22:31–39, 2002
[PubMed]
 
Dollfus S, Petit M, Menard JF, et al: Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. J Autism Dev Disord 22:47–60, 1992
[PubMed]
 
Donnelly M, Rapoport JL, Potter WZ, et al: Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. Arch Gen Psychiatry 46:205–212, 1989
[PubMed]
 
Donovan SJ, Stewart JW, Nunes EV, et al: Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 157:818–820, 2000
[PubMed]
 
Douglass HM, Moffitt TE, Dar R, et al: Obsessive-compulsive disorder in a birth cohort of 18-year-olds: prevalence and predictors. J Am Acad Child Adolesc Psychiatry 34:1424–1431, 1995
[PubMed]
 
Dow SP, Sonies BC, Scheib D, et al: Practical guidelines for the assessment and treatment of selective mutism. J Am Acad Child Adolesc Psychiatry 34:836–846, 1995
[PubMed]
 
du Verglas G, Banks SR, Guyer KE: Clinical effects of fenfluramine on children with autism: a review of the research. J Autism Dev Disord 18:297–308, 1988
 
Dummit ES III, Klein RG, Tancer NK, et al: Fluoxetine treatment of children with selective mutism: an open trial. J Am Acad Child Adolesc Psychiatry 35:615–621, 1996
[PubMed]
 
Dunbar F, Kusumakar V, Daneman D, et al: Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 161:918–920, 2004
[PubMed]
 
Dunn V, Goodyer IM: Longitudinal investigation into childhood- and adolescence-onset depression: psychiatric outcome in early adulthood. Br J Psychiatry 188:216–222, 2006
[PubMed]
 
Durkin JP 2nd: Gabapentin in complicated school refusal. J Am Acad Child Adolesc Psychiatry 41:632–633, 2002
[PubMed]
 
Eggers C, Bunk D: The long-term course of childhood-onset schizophrenia: a 42-year follow-up. Schizophr Bull 23:105–117, 1997
[PubMed]
 
Ekman G, Miranda-Linne F, Gillberg C, et al: Fenfluramine treatment of twenty children with autism. J Autism Dev Disord 19:511–532, 1989
[PubMed]
 
Emslie GJ, Rush AJ, Weinberg WA, et al: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031–1037, 1997
[PubMed]
 
Emslie GJ, Wagner KD, Riddle M, et al: Efficacy and safety of paroxetine in juvenile OCD. Poster presented at the 153rd annual meeting of the American Psychiatric Association, Chicago, IL, May 13–18, 2000
 
Emslie GJ, Heiligenstein JH, Wagner KD, et al: Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205–1215, 2002
[PubMed]
 
Emslie GJ, Wagner KD, Kutcher S, et al: Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 45:709–719, 2006
[PubMed]
 
Emslie GJ, Findling RL, Yeung PP, et al: Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 46:479–488, 2007a
 
Emslie GJ, Yeung PP, Kunz NR: Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder. CNS Spectr 12:223–233, 2007b
 
Engelhardt DM, Polizos P, Waizer J, et al: A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. J Autism Child Schizophr 3:128–137, 1973
 
Ernst M, Magee HJ, Gonzalez NM, et al: Pimozide in autistic children. Psychopharmacol Bull 28:187–191, 1992
[PubMed]
 
Famularo R, Kinscherff R, Fenton T: Propranolol treatment for childhood posttraumatic stress disorder, acute type: a pilot study. Am J Dis Child 142:1244–1247, 1988
[PubMed]
 
Fankhauser MP, Karumanchi VC, German ML et al: A double blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53:77–82, 1992
[PubMed]
 
Faretra G, Dooher L, Dowling J: Comparison of haloperidol and fluphenazine in disturbed children. Am J Psychiatry 126:1670–1673, 1970
[PubMed]
 
Fatemi SH, Realmuto GM, Khan L, et al: Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 28:303–307, 1998
[PubMed]
 
Feldman HM, Kolmen BK, Gonzaga AM, et al: Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 38:587–593, 1999
[PubMed]
 
Fenichel R: Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolesc Psychopharmacol 5:155–156, 1995
 
Findling RL: Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol 6:165–175, 1996
[PubMed]
 
Findling RL, Lopez FA: Efficacy of transdermal methylphenidate with reference to Concerta in ADHD. Presented at the 25th annual meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, CA, October 18–23, 2005
 
Findling RL, McNamara NK, Gracious BL, et al: Combination lithium and divalproex sodium in pediatric bipolarity. J Am Acad Child Adolesc Psychiatry 42:895–901, 2003a
 
Findling RL, McNamara NK, Youngstrom EA, et al. A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 42:170–175, 2003b
 
Findling RL, McNamara NK, Gracious BL: Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14:287–294, 2004
[PubMed]
 
Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:409–417, 2005
[PubMed]
 
Findling RL, Krishman S, Biederman J: Efficacy and safety of lisdexamfetamine (LDX) in children aged 6 to 12 years with attention-deficit/hyperactivity disorder (ADHD). Presented at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, October 28, 2006a
 
Findling RL, Reed MD, O'Riordan MA, et al: Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 45:792–800, 2006b
 
Findling RL, Nyilas M, Auby P, et al: Tolerability of aripiprazole in the treatment of adolescents with schizophrenia. New research poster presented at the 160th annual meeting of the American Psychiatric Association, San Diego, CA, May 19–24, 2007
 
Flakierska-Praquin N, Lindstrom M, Gillberg C: School phobia with separation anxiety disorder: a comparative 20- to 29-year follow-up study of 35 school refusers. Compr Psychiatry 38:17–22, 1997
[PubMed]
 
Flament MF, Rapoport JL, Berg CJ, et al: Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 42:977–983, 1985
[PubMed]
 
Frazier JA, Biederman J, Tohen M, et al: A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11:239–250, 2001
[PubMed]
 
Fristad MA, Goldberg-Arnold JS, Gavazzi SM, et al: Multifamily psychoeducation groups in the treatment of children with mood disorders. J Marital Fam Ther 29:491–504, 2003
[PubMed]
 
Gadow KD, Sverd J, Sprafkin J, et al: Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 52:444–455, 1995
[PubMed]
 
Gadow KD, Sverd J, Sprafkin J, et al: Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder [see comments]. Arch Gen Psychiatry 56:330–336, 1999
[PubMed]
 
Gaffney GR, Perry PJ, Lund BC, et al: Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 41:330–336, 2002
[PubMed]
 
Gammon GD, Brown TE: Fluoxetine and methylphenidate in combination for treatment of attention deficit and comorbid depressive disorder. J Child Adolesc Psychopharmacol 3:1–10, 1993
 
Gastaut H, Zifkin B, Rufo M: Compulsive respiratory stereotypies in children with autistic features: polygraphic recording and treatment with fenfluramine. J Autism Dev Disord 17:391–406, 1987
[PubMed]
 
Geller B, Cooper TB, Chestnut EC, et al: Preliminary data on the relationship between nortriptyline plasma level and response in depressed children. Am J Psychiatry 143:1283–1286, 1986
[PubMed]
 
Geller B, Cooper TB, Graham DL, et al: Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design. Psychopharmacol Bull 26:85–90, 1990
[PubMed]
 
Geller B, Cooper TB, Graham DL, et al: Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 31:34–44, 1992
[PubMed]
 
Geller B, Cooper TB, Sun K, et al: Double blind and placebo controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 37:171–178, 1998
[PubMed]
 
Geller B, Zimerman B, Williams M, et al: Diagnostic characteristics of 93 cases of prepubertal and early adolescent bipolar disorder phenotype by gender, puberty and comorbid attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:157–164, 2000
[PubMed]
 
Geller B, Tillman MS, Craney JL, et al: Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch Gen Psychiatry 61:459–467, 2004
[PubMed]
 
Geller DA, Biederman J, Wagner KD, et al: Comorbid psychiatric illness and response to treatment, relapse rates, and behavioral adverse event incidence in pediatric OCD. Poster presented at the 41st annual meeting of the New Clinical Drug Evaluation Unit, Phoenix, AZ, May 28–31, 2001a
 
Geller DA, Hoog SL, Heiligenstein JH, et al: Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 40:773–779, 2001b
 
Geller DA, Hoog SL, Heiligenstein JH, et al: Predictive factors in response to fluoxetine treatment for pediatric OCD. Poster presented at the 48th annual meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI, October 23–28, 2001c
 
Geller DA, Wagner KD, Emslie G, et al: Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 43:1387–1396, 2004
[PubMed]
 
Geller E, Ritvo ER, Freeman BJ, et al: Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 307:165–169, 1982
[PubMed]
 
Gelperin K: Psychiatric adverse events associated with drug treatment of ADHD: review of postmarketing safety data. U.S. Food and Drug Administration Pediatric Advisory Committee, March 22, 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4210s_15_Gelperin_Review%20of%20Postmarking%20Safety.ppt. Accessed December 2008.
 
George MS, Trimble MR, Robertson MM: Fluvoxamine and sulpiride in comorbid obsessive compulsive disorder and Gilles de la Tourette's syndrome. Hum Psychopharmacol 8:327–334, 1993
 
Ghaziuddin M, Tsai L, Ghaziuddin N, et al: Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry 30:508–509, 1991
[PubMed]
 
Giaconia RM, Reinherz HZ, Silverman AB, et al: Traumas and posttraumatic stress disorder in a community population of older adolescents. J Am Acad Child Adolesc Psychiatry 34:1369–1380, 1995
 
Gibbons RD, Hur K, Bhaumik DK, et al: The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 163:1898–1904, 2006
[PubMed]
 
Gibson AP, Crismon ML, Mican LM, et al: Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation. Int Clin Psychopharmacol 22:101–105, 2007
[PubMed]
 
Gilbert DL, Batterson JR, Sethuraman G, et al: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 43:206–214, 2004
[PubMed]
 
Gittelman-Klein R, Klein DF: Controlled imipramine treatment of school phobia. Arch Gen Psychiatry 25:204–207, 1971
 
Gittelman-Klein R, Mannuzza S: Hyperactive boys almost grown up, III: methylphenidate effects on ultimate height. Arch Gen Psychiatry 45:1131–1134, 1988
 
Glod CA, Lynch A, Flynn E, et al: Bupropion SR in the treatment of adolescent depression. Poster presented at the 40th Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, 2000
 
Goetz CG, Tanner CM, Wilson RS, et al: Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods. Ann Neurol 21:307–310, 1987
[PubMed]
 
Golwyn DH, Sevlie CP: Phenelzine treatment of selective mutism in four prepubertal children. J Child Adolesc Psychopharmacol 9:109–113, 1999
[PubMed]
 
Golwyn DH, Weinstock RC: Phenelzine treatment of elective mutism: a case report. J Clin Psychiatry 51:384–385, 1990
[PubMed]
 
Goodman WK, Price LH, Rasmusen SA et al: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS). New Haven, CT, Department of Psychiatry, Yale University School of Medicine, 1991
 
Gordon CT, State RC, Nelson JE, et al: A double-blind comparison of clomipramine, desipramine, and of autistic disorder. Arch Gen Psychiatry 50:441–447, 1993
[PubMed]
 
Graae F, Milner J, Rizzotto L, et al: Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33:372–376, 1994
[PubMed]
 
Grados M, Scahill L, Riddle MA: Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. Child Adolesc Clin N Am 8:617–634, 1999
[PubMed]
 
Gram LF, Rafaelsen OJ: Lithium treatment of psychotic children and adolescents. A controlled clinical trial. Acta Psychiatr Scand 48:253–260, 1972
[PubMed]
 
Green WH: Child and Adolescent Clinical Psychopharmacology, 3rd Edition. Philadelphia, PA, Lippincott Williams & Wilkins, 2001
 
Greenhill LL, Halperin JM, Abikoff H: Stimulant medications. J Am Acad Child Adolesc Psychiatry 38:503–512, 1999
[PubMed]
 
Greenhill LL, Findling RL, Swanson JM: A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:e39, 2002
 
Greenhill LL, Swanson JM, Steinhoff K, et al: A pharmacokinetic/pharmacodynamic study comparing a single morning dose of Adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiatry 42:1234–1241, 2003
[PubMed]
 
Greenhill LL, Vitiello B, Abikoff HB, et al: Outcome results from the NIMH, multi-site, preschool ADHD treatment study (PATS). Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19–24, 2004
 
Greenhill LL, Ball R, Levine AJ, et al: Extended release dexmethylphenidate in children and adolescents with ADHD. Presented at the 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA, May 21–25, 2005
 
Greenhill LL, Biederman J, Boellner SW, et al: A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:503–511, 2006a
 
Greenhill LL, Kollins S, Abikoff H, et al: Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45:1284–1293, 2006b
 
Gunther T, Herpertz-Dahlmann B, Jolles J, et al: The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder. J Child Adolesc Psychopharmacol 16:725–735, 2006
[PubMed]
 
Greist JH, Jefferson JW, Kobak KA, et al: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 52:53–60, 1995
[PubMed]
 
Groden G, Groden J, Dondey M, et al: Effects of fenfluramine on the behavior of autistic individuals. Res Dev Disabil 8:203–211, 1987
[PubMed]
 
Haas M, Unis AS, Copenhaver M, et al: Efficacy and safety of risperidone in adolescents with schizophrenia. Presented at the 160th Annual Meeting of the American Psychiatric Association, San Diego, CA, May 19–24, 2007
 
Hamilton BE, Minino AM, Martin JA, et al: Annual summary of vital statistics: 2005. Pediatrics 119:345–360, 2007
[PubMed]
 
Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 32:50–55, 1959
[PubMed]
 
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62, 1960
[PubMed]
 
Hammerness PG, Vivas FM, Geller DA: Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatr 148:158–165, 2006
[PubMed]
 
Handen BL, Johnson CR, Lubetsky M: Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245–255, 2000
[PubMed]
 
Harmon RJ, Riggs PD: Clonidine for posttraumatic stress disorder in preschool children. J Am Acad Child Adolesc Psychiatry 35:1247–1249, 1996
[PubMed]
 
Hayden F: Long-term remission of schizophrenia in an adolescent treated with quetiapine. J Child Adolesc Psychopharmacol 11:289–293, 2001
[PubMed]
 
Hazaray E, Ehret J, Posey DJ, et al: Intramuscular ziprasidone for acute agitation in adolescents. J Child Adolesc Psychopharmacol 14:464–470, 2004
[PubMed]
 
Hazell PL, Stuart JE: A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 42:886–894, 2003
[PubMed]
 
Herman BH, Asleson GS, Powell A, et al: Cardiovascular and other physical effects of acute administration of naltrexone in autistic children. J Child Adolesc Psychopharmacol 3:157–168, 1993
 
Ho HH, Lockitch G, Eaves L, et al: Blood serotonin concentrations and fenfluramine therapy in autistic children. J Pediatr 108:465–469, 1986
[PubMed]
 
Hollander E, Kaplan A, Cartwright C, et al: Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol 15:132–135, 2000
[PubMed]
 
Hollander E, Phillips A, Chaplin W, et al: A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:582–589, 2005
[PubMed]
 
Horrigan JP: Guanfacine for PTSD nightmares. J Am Acad Child Adolesc Psychiatry 35:975–976, 1996
[PubMed]
 
Horvath K, Stafanatos G, Sokolski KN, et al: Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 9:9–15, 1998
[PubMed]
 
Howlin P: Autism and intellectual disability: diagnostic and treatment issues. J R Soc Med 93:351–355, 2000
[PubMed]
 
Hughes CW, Emslie GJ, Crismon MJ, et al: The Texas Children's Medication Algorithm Project: Update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 46:667–686, 2007
[PubMed]
 
Hunt RD, Capper L, O'Connell P: Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol 1:87–102, 1990
 
Hunt RD, Amsten AF, Asbell MD: An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:50–54, 1995
[PubMed]
 
Jaselskis CA, Cook EH, Fletcher KE, et al: Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322–327, 1992
[PubMed]
 
Jasinski D, Krishman S: Abuse liability of intravenous lisdexamfetamine (LDX; NRP104). Presented at the 58th Institute on Psychiatric Services, New York, NY, October 6, 2006a
 
Jasinski D, Krishman S: A double-blind, randomized, placebo- and active-controlled, 6-period crossover study to evaluate the likeability, safety, and abuse potential of lisdexamfetamine dimesylate (LDX) in adult stimulant abusers. Presented at the 2006 US Psychiatric and Mental Health Congress, New Orleans, LA, November 17, 2006b
 
Jensen PS, Bhatara VS, Vitiello B, et al: Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 38:557–565, 1999
[PubMed]
 
Kaufman J, Birmaher B, Brent D, et al: Schedule for Affective Disorders and Schizophrenia for School Age Children, Present and Lifetime Versions (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988, 1997
[PubMed]
 
Kafantaris V, Coletti DJ, Dicker R, et al: Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatry 40:1448–1456, 2001a
 
Kafantaris V, Dicker R, Coletti DJ, et al: Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania. J Am Acad Child Adolesc Psychopharmacol 11:409–413, 2001b
 
Kafantaris V, Coletti DJ, Dicker R, et al: Lithium treatment of acute mania in adolescents: a large open trial. J Am Acad Child Adolesc Psychiatry 42:1038–1045, 2003
[PubMed]
 
Kafantaris V, Coletti DJ, Dicker R, et al: Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. J Am Acad Child Adolesc Psychiatry 43:984–993, 2004
[PubMed]
 
Kappagoda C, Schell DN, Hanson RM, et al: Clonidine overdose in childhood: implications of increased prescribing. J Paediatr Child Health 34:508–512, 1998
[PubMed]
 
Kashani JH, Orvaschel H: Anxiety disorders in mid-adolescence: a community sample. Am J Psychiatry 145:960–964, 1988
[PubMed]
 
Kashani JH, Sherman DD: Childhood depression: epidemiology, etiological models, and treatment implications. Integr Psychiatry 6:1–8, 1988
 
Kastner T: Secretin and autism. Except Health Care 9:45–46, 1998
 
Keller MB, Lavori PW, Wunder J, et al: Chronic course of anxiety disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 31:595–599, 1992
[PubMed]
 
Keller MB, Ryan ND, Strober M, et al: Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762–772, 2001
[PubMed]
 
Kemner C, Willemsen-Swinkels SHN, DeJonge M, et al: Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22:455–460, 2002
[PubMed]
 
Kemph JP, DeVane CL, Levin GM, et al: Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatry 32:577–581, 1993
[PubMed]
 
Kennard B, Silva S, Vitiello B, et al: Remission and residual symptoms after short-term treatment in the treatment of adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 45:1404–1411, 2006
[PubMed]
 
Kerbeshian J, Burd L, Fisher W: Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol 7:401–405, 1987
[PubMed]
 
Kessler RC, Adler L, Barkley R, et al: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716–723, 2006
[PubMed]
 
Khan SS, Mican LM, Khan SS, et al: A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. J Child Adolesc Psychopharmacol 16:671–677, 2006
[PubMed]
 
Kim BN, Lee CB, Hwang JW, et al: Effectiveness and safety of risperidone for children and adolescents with chronic tic or Tourette disorders in Korea. J Child Adolesc Psychopharmacol 15:318–324, 2005
[PubMed]
 
King BH, Wright DM, Handen BL, et al: Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 40:658–665, 2001
[PubMed]
 
Kisicki J, Fiske K, Scheckner B, et al: Abrupt cessation of guanfacine extended release in healthy young adults. Presented at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, October 24–29, 2006
 
Klein RG, Koplewicz HS, Kanner A: Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 31:21–28, 1992
[PubMed]
 
Klein RG, Abikoff H, Klass E, et al: Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 54:1073–1080, 1997
[PubMed]
 
Klykylo WM, Feldis D, O'Grady D, et al: Clinical effects of fenfluramine in ten autistic subjects. J Autism Dev Disord 15:417–423, 1985
[PubMed]
 
Knorring A, Olsson GI, Thomsen PH, et al: A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 26:311–315, 2006
 
Kofoed L, Tadepalli G, Oesterheld JR, et al: Case series: clonidine has no systematic effects on PR or QTc intervals in children. J Am Acad Child Adolesc Psychiatry 38:1193–1196, 1999
[PubMed]
 
Kohler JA, Shortland G, Rolles CJ: Effect of fenfluramine on autistic symptoms. Br Med J (Clin Res Ed) 295:885, 1987
[PubMed]
 
Kolmen BK, Feldman HM, Handen BL, et al: Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 34:223–231, 1995
[PubMed]
 
Kolmen BK, Felman HM, Handen BL, et al: Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 36:1570–1578, 1997
[PubMed]
 
Kowatch RA, Carmody TJ, Suppes T, et al: Acute and continuation pharmacological treatment of children and adolescents with bipolar disorders: a summary of two previous studies. Acta Neuropsychiatrica 12:145–149, 2000a
 
Kowatch RA, Suppes T, Carmody TJ, et al: Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 39:713–720, 2000b
 
Kowatch RA, Fristad M, Birmaher B, et al: Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:213–235, 2005
[PubMed]
 
Kramer JR, Loney J, Ponto LB, et al: Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry 39:517–524, 2000
[PubMed]
 
Kranzler H, Roofeh D, Gerbino-Rosen G, et al: Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 44:55–63, 2005
[PubMed]
 
Krasny L, Williams BJ, Provencal S, et al: Social skills interventions for the autism spectrum: essential ingredients and a model curriculum. Child Adolesc Psychiatric Clin N Am 12:107–122, 2003
[PubMed]
 
Kratochvil CJ, Heiligenstein JH, Dittmann R, et al: Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41:776–784, 2002
[PubMed]
 
Kratochvil CJ, Vaughan BS, Harrington MJ, et al: Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 4:1165–1174, 2003
[PubMed]
 
Kroes M, Kalfe AC, Kessels AG, et al: Child psychiatric diagnoses in a population of Dutch schoolchildren aged 6 to 8 years. J Am Acad Child Adolesc Psychiatry 40:1401–1409, 2001
[PubMed]
 
Kryzhanovskaya L, Schultz C, McDougle J, et al: A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. Presented at the 159th annual meeting of the American Psychiatric Association, Toronto, Canada, May 20–25, 2006
 
Kumra S: The diagnosis and treatment of children and adolescents with schizophrenia: "My mind is playing tricks on me." Child Adolesc Psychiatr Clin N Am 9:183–199, 2000
[PubMed]
 
Kumra S, Frazier JA, Jacobsen LK, et al: Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090–1097, 1996
[PubMed]
 
Kumra S, Jacobsen LK, Lenane M, et al: Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 37:377–385, 1998
[PubMed]
 
Kunz NR, Khan A, Nicoloacopoulos E, et al: Venlafaxine extended-release for GAD treatment in children and adolescents. Poster presented at the 155th annual meeting of the American Psychiatric Association, Philadelphia, PA, May 18–23, 2002
 
Kuperman S, Stewart MA: Use of propranolol to decrease aggressive outbursts in younger patients. Psychosomatics 28:315–319, 1987
[PubMed]
 
Kusumakar V, Yatham LN: An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 72:145–148, 1997
[PubMed]
 
Kutcher SP, MacKenzie S: Successful clonazepam treatment of adolescents with panic disorder. J Clin Psychopharmacol 8:299–301, 1988
[PubMed]
 
Kutcher SP, Reiter S, Gardner DM, et al: The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatr Clin North Am 15:41–67, 1992
[PubMed]
 
Kutcher SP, Boulos C, Ward B, et al: Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 33:686–694, 1994
[PubMed]
 
Kye CH, Waterman GS, Ryan ND, et al: A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. J Am Acad Child Adolesc Psychiatry 35:1139–1144, 1996
[PubMed]
 
Lafferty JE, Constantino JN: Fluvoxamine in selective mutism. J Am Acad Child Adolesc Psychiatry 37:12–13, 1998
[PubMed]
 
Law SF, Schachar RJ: Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 38:944–951, 1999
[PubMed]
 
LeBlanc JC, Binder CE, Armenteros JL, et al: Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. Int Clin Psychopharmacol 20:275–283, 2005
[PubMed]
 
Leboyer M, Bouvard MP, Lensing P, et al: Opioid excess hypothesis of autism: a double-blind study of naltrexone. Brain Dysfunction 3:285–298, 1990
 
Leboyer M, Bouvard MP, Launay JM, et al: Brief report: a double-blind study of naltrexone in infantile autism. J Autism Dev Disord 22:309–319, 1992
[PubMed]
 
Leckman JF: Tourette's syndrome. Lancet 360:1577–1586, 2002
[PubMed]
 
Leckman JF, Detlor J, Harcherik DF, et al: Short- and long-term treatment of Tourette's syndrome with clonidine: a clinical perspective. Neurology 35:343–351, 1985
[PubMed]
 
Leckman JF, Hardin MT, Riddle MA, et al: Clonidine treatment of Gilles De La Tourette's syndrome. Arch Gen Psychiatry 48:324–328, 1991
[PubMed]
 
Lena B: Lithium in child and adolescent psychiatry. Arch Gen Psychiatry 36:854–855, 1979
[PubMed]
 
Leonard HL, Swedo SE, Rapoport JL, et al: Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry 46:1088–1092, 1989
[PubMed]
 
Leonard HL, Swedo SE, Lenane MC, et al: A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 48:922–927, 1991
[PubMed]
 
Leonard HL, Swedo SE, Lanane MC, et al: A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 50:429–439, 1993
[PubMed]
 
Leonard HL, Topol D, Bukstein O, et al: Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 33:792–794, 1994
[PubMed]
 
Lepola U, Leinonen E, Koponen H: Citalopram in the treatment of early onset panic disorder and school phobia. Pharmacopsychiatry 29:30–32, 1996
[PubMed]
 
Leventhal BL, Cook EH Jr, Morford M, et al: Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatry Clin Neurosci 5:307–315, 1993
[PubMed]
 
Lewinsohn PM, Klein DN, Seeley JR: Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J Am Acad Child Adolesc Psychiatry 34:454–463, 1995
[PubMed]
 
Libby AM, Brent DA, Morrato EH, et al: Decline in treatment of pediatric depression after FDA advisory on risk suicidality with SSRIs. Am J Psychiatry 164:884–891, 2007
[PubMed]
 
Liberthson RR: Sudden death from cardiac causes in children and young adults. N Engl J Med 334:1039–1044, 1996
[PubMed]
 
Lichter DG, Jackson LA: Predictors of clonidine response in Tourette's syndrome: implications and inferences. J Child Neurol 11:93–97, 1996
[PubMed]
 
Liebowitz MR, Turner SM, Piacentini J, et al: Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 41:1431–1438, 2002
[PubMed]
 
Linday LA, Tsiouris JA, Cohen IL, et al: Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design. J Neural Transm 108:593–611, 2001
[PubMed]
 
Looff D, Grimley P, Kuller F, et al: Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry 34:703–704, 1995
[PubMed]
 
Macaluso E, Frith CD, Driver J: Modulation of human visual cortex by cross-modal spatial attention. Science 289:1206–1208, 2000
[PubMed]
 
Malone RP, Delaney MA, Luebbert JF, et al: A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57:649–654, 2000
[PubMed]
 
Malone RP, Cater J, Sheikh RM, et al: Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40:887–894, 2001
[PubMed]
 
Mancini C, Van Amerigen M, Oakman JM, et al: Serotonergic agents in the treatment of social phobia in children and adolescents: a case series. Depress Anxiety 10:33–39, 1999
[PubMed]
 
March JS, Biederman J, Wolkow R, et al: Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280:1752–1756, 1998
[PubMed]
 
March JS, Franklin ME, Leonard H, et al: Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 61:344–347, 2007
[PubMed]
 
Markowitz S, Cuellar A: Antidepressants and youth: healing or harmful? Soc Sci Med 64:2138–2151, 2007
[PubMed]
 
Martin A, Koenig K, Scahill L, et al: Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99–107, 1999
[PubMed]
 
Masi G, Toni C, Mucci M, et al: Paroxetine in child and adolescent outpatients with panic disorder. J Child Adolesc Psychopharmacol 11:151–157, 2001
[PubMed]
 
Maughan B, Rowe R, Messer J, et al: Conduct disorder and oppositional defiant disorder in a national sample: developmental epidemiology. J Child Psychol Psychiatry 45:609–621, 2004
[PubMed]
 
McClellan J, Werry J: Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 40 (7 suppl):4S–23S, 2001
 
McClellan J, Kowatch R, Findling RL: Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 46:107–125, 2007
[PubMed]
 
McConville BJ, Fogelson MH, Norman AB, et al: Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am J Psychiatry 148:793–794, 1991
[PubMed]
 
McConville BJ, Sanberg PR, Fogelson MH, et al: The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry 31:832–840, 1992
[PubMed]
 
McConville BJ, Arvanitis L, Thyrum P, et al: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine in adolescents with selected psychotic disorders. Eur Neuropsychopharmacol 9 (suppl 5):S267, 1999
 
McCracken JT, Biederman J, Greenhill LL, et al: Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 42:673–683, 2003
[PubMed]
 
McDougle CJ, Kresch LE, Posey DJ: Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30:427–435, 2000a
 
McDougle CJ, Scahill L, McCracken JT, et al: Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 9:201–224, 2000b
 
McDougle CJ, Kem DL, Posey DJ: Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41:921–927, 2002
[PubMed]
 
McDougle CJ, Martin A, Aman M, et al: New findings from the RUPP autism network study of risperidone. Presented at the 51st annual meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19–24, 2004
 
McGough JJ, Biederman J, Wigal SB, et al: Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:530–538, 2005
[PubMed]
 
McGough J, McCracken J, Swanson J, et al: Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45:1314–1322, 2006
[PubMed]
 
McKnew DH, Cytryn L, Buchsbaum MS, et al: Lithium in children of lithium-responding parents. Psychiatry Res 4:171–180, 1981
[PubMed]
 
Mei Z, Grummer-Strawn LM, Thompson D, et al: Shifts in percentiles of growth during early childhood: analysis of longitudinal data from the California Child Health and Development Study. Pediatrics 113:e617–e627, 2004
 
Meighen KG: Duloxetine treatment of pediatric chronic pain and comorbid major depressive disorder. J Child Adolesc Psychopharmacol 17:121–127, 2007
[PubMed]
 
Melmed RD, Patel A, Konow J, et al: Efficacy and safety of guanfacine extended release for ADHD treatment. Presented at the 53rd annual meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA, October 24–29, 2006
 
Melvin GA, Tonge BJ, King NJ, et al: A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolescent Psychiatry 45:1151–1161, 2006
[PubMed]
 
Messenheimer JA: Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 25:S14–S18, 1998
 
Michelson D: Active comparator studies in the atomoxetine clinical development program. Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, October 19–24, 2004
 
Michelson D, Faries D, Wernicke J, et al: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:1–9, 2001
 
Michelson D, Allen AJ, Busner J, et al: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896–1901, 2002
[PubMed]
 
Michelson D, Adler L, Spencer T, et al: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120, 2003
[PubMed]
 
Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389, 1979
[PubMed]
 
Mosholder A: Psychiatric adverse events in clinical trials of drugs for attention deficit hyperactivity disorder (ADHD). Available at: Food and Drug Administration Website, 2006
 
Mozes T, Ebert T, Michal SE, et al: An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 16:393–403, 2006
[PubMed]
 
Mufson L, Sills R: Interpersonal Psychotherapy for depressed adolescents (IPT-A): an overview. Nord J Psychiatry 60:431–437, 2006
[PubMed]
 
Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette's Disorder. J Child Adolesc Psychopharmacol 13:295–299, 2003
[PubMed]
 
Murphy TK, Bengtson MA, Soto O, et al: Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 8:489–490, 2005
[PubMed]
 
MTA Cooperative Group: 14 Month randomized clinical trial of treatment strategies for children and attention deficit hyperactivity disorder. Arch Gen Psychiatry 56:1073–1086, 1999
 
MTA Cooperative Group: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113:762–769, 2004
 
MTA Cooperative Group: Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 46:1015–1027, 2007
 
Nader KO, Kriegler JA, Blake DD, et al: Clinician administered PTSD Scale for Children and Adolescents for (DSM-IV) (CAPS-CA). Current and Lifetime Diagnostic Version, and Instruction Manual. A National Center for PTSD/UCLA Trauma Psychiatry Program. Los Angeles, CA, National Center for PTSD and UCLA Trauma Psychiatry Program, 1996
 
Nagaraj R, Singhi P, Malhi P: Risperidone in children with autism: randomized, place-controlled, double-blind study. J Child Neurol 21:450–455, 2006
[PubMed]
 
Naruse H, Nagahata M, Nakane Y, et al: A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 48:173–184, 1982
[PubMed]
 
Newcorn JH, Spencer TJ, Biederman J, et al: Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 44:240–248, 2005
[PubMed]
 
Nicolson R, Craven-Thuss B, Smith J, et al: A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette's disorder. J Am Acad Child Adolesc Psychiatry 44:640–646, 2005
[PubMed]
 
Niederhofer H, Staffen W, Mair A: A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. J Psychopharmacol 17:113–119, 2003
[PubMed]
 
Olvera RL, Pliszka SR, Luh J, et al: An open trial of venlafaxine in children and adolescents with ADHD. J Child Adolesc Psychopharmacol 6:241–250, 1996
[PubMed]
 
Overall J, Pfefferbaum B: A Brief Psychiatric Rating Scale for Children. Innovations 3:264, 1984
 
Owley T, McMahon W, Cook EH, et al: Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry 40:1293–1299, 2001
[PubMed]
 
Owley T, Walton L, Salt J, et al: An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 44:343–348, 2005
[PubMed]
 
Pandina GJ, Aman MG, Findling RL, et al: Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol 16:379–392, 2006
[PubMed]
 
Pangalila-Ratulangi EA: Pilot evaluation of Orap (pimozide, R 6238) in child psychiatry. Psychiatr Neurol Neurochir 76:17–27, 1973
[PubMed]
 
Pappadopulos E, Macintyre Ii JC, Crismon ML, et al: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), Part II. J Am Acad Child Adolesc Psychiatry 42:145–161, 2003
[PubMed]
 
Pappadopulos E, Woolston BA, Chait A, et al: Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Am Acad Child Adolesc Psychiatry 15:27–39, 2006
[PubMed]
 
Patel NC, DelBello MP, Bryan HS, et al: Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 45:289–297, 2006
[PubMed]
 
Pavuluri MN, Henry DB, Carbray JA, et al: Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord 82 (suppl 1):S103–S111, 2004
 
Pavuluri MN, Henry DB, Carbray JA, et al: A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol 16:336–350, 2006
[PubMed]
 
Pediatric OCD Treatment Study (POTS) Team: Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder. JAMA 292:1969–1976, 2004
 
Pelham WE, Wheeler T, Chronis A: Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 27:190–205, 1998
[PubMed]
 
Pelham WE, Burrows-MacLean L, Gnagy E, et al: Once-a-day OROS methylphenidate versus tid methylphenidate in natural settings. Presented at the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, IL, October 19–24, 1999
 
Pelham WE, Gnagy EM, Burrows-MacLean L, et al: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:e105, 2001
 
Pelham WE, Burrows-MacLean L, Gnagy EM, et al: Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 13:111–126, 2005
[PubMed]
 
Perry R, Campbell M, Adams P, et al: Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 28:87–92, 1989
[PubMed]
 
Piacentini JC, Chang SW: Behavioral treatments for tic suppression: habit reversal training. Adv Neurol 99:227–233, 2006
[PubMed]
 
Piggott LR, Gdowski CL, Villanueva D, et al: Side effects of fenfluramine in autistic children. J Am Acad Child Psychiatry 25:287–289, 1986
[PubMed]
 
Pine DS, Cohen P, Gurley D, et al: The risk for early adulthood anxiety and depressive disorders in adolescent with anxiety and depressive disorders. Arch Gen Psychiatry 55:56–64, 1998
[PubMed]
 
Pliszka SR, Carlson CL, Swanson JM: ADHD With Comorbid Disorders: Clinical Assessment and Management. New York, Guilford, 1999
 
Pliszka SR, Crismon ML, Hughes CW, et al: The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642–657, 2006a
 
Pliszka SR, Matthews TL, Braslow KJ, et al: Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 45:520–526, 2006b
 
Pool D, Bloom W, Mielke DH, et al: A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 19:99–104, 1976
[PubMed]
 
Popper CW: Medical unknowns and ethical consent: prescribing psychotropic medications for children in the face of uncertainty, in Psychiatric Pharmacosciences of Children and Adolescents. Edited by Popper CW. Washington, DC, American Psychiatric Press, 1987, pp 127–161
 
Popper CW: Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:605–646, 2000
[PubMed]
 
Popper CW, Ziminitzky B: Sudden death putatively related to desipramine treatment in youth: a fifth case and a review of speculative mechanisms. J Child Adolesc Psychopharmacol 5:283–300, 1995
 
Posey DJ, Walsh KH, Wilson GA, et al: Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol 9:273–276, 1999
[PubMed]
 
Posey DJ, Guenin KD, Kohn AE, et al: A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychiatry 11:267–277, 2001
[PubMed]
 
Potenza MN, Holmes JP, Kanes SJ, et al: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37–44, 1999
[PubMed]
 
Poulton A: Growth on stimulant medication: clarifying the confusion: a review. Arch Dis Child 90:801–806, 2005
[PubMed]
 
Poznanski EO, Freman LN, Mokros HB: Children's Depression Rating Scale–Revised. Psychopharmacol Bull 21:979–989, 1985
 
Preskorn SH, Weller EB, Weller RA: Depression in children: relationship between plasma imipramine levels and response. J Clin Psychiatry 43:450–453, 1982
[PubMed]
 
Prince JB, Wilens TE, Biederman J, et al: A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:193–204, 2000
[PubMed]
 
Puig-Antich J, Perel JM, Lupatkin W, et al: Plasma levels of imipramine (IMI) and desmethylimipramine (DMI) and clinical response in prepubertal major depressive disorder: a preliminary report. J Am Acad Child Psychiatry 18:616–627, 1979
[PubMed]
 
Puig-Antich J, Perel JM, Lupatkin W, et al: Imipramine in prepubertal major depressive disorders. Arch Gen Psychiatry 44:81–89, 1987
[PubMed]
 
Quinn D, Wigal S, Swanson J, et al: Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43:1422–1429, 2004
[PubMed]
 
Quintana H, Birmaher B, Stedge D, et al: Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25:283–294, 1995
[PubMed]
 
Rasgon NL: The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence. J Clin Psychopharmacol 24:322–334, 2004
[PubMed]
 
Realmuto GM, Erickson WD, Yellin AM, et al: Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 141:440–442, 1984
[PubMed]
 
Realmuto GM, Jensen J, Klykylo W, et al: Untoward effects of fenfluramine in autistic children. J Clin Psychopharmacol 6:350–355, 1986
[PubMed]
 
Realmuto GM, August GJ, Garfinkel BD: Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 9:122–125, 1989
[PubMed]
 
Regeur L, Pakkenberg B, Fog R, et al: Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. J Neurol Neurosurg Psychiatry 49:791–795, 1986
[PubMed]
 
Reinblatt SP, Walkup JT: Psychopharmacologic treatment of pediatric anxiety disorders. Child Adolesc Psychiatric Clin N Am 14:877–908, 2005
[PubMed]
 
Remington G, Sloman L, Konstantareas M, et al: Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 21:440–444, 2001
[PubMed]
 
Renaud J, Birmaher B, Wassick SC, et al: Use of selective serotonin reuptake inhibitors for the treatment of childhood panic disorder: a pilot study. J Child Adolescent Psychopharmacology 9:73–83, 1999
[PubMed]
 
Research Units on Pediatric Psychopharmacology Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279–1285, 2001
 
Research Units on Pediatric Psychopharmacology Anxiety Study Group: The pediatric anxiety rating scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry 41:1061–1069, 2002a
 
Research Units on Pediatric Psychopharmacology Anxiety Study Group: Treatment of pediatric anxiety disorders: an open-label extension of the Research Units on Pediatric Psychopharmacology anxiety study. J Am Acad Child Adolesc Psychiatry 12:175–188, 2002b
 
Research Units on Pediatric Psychopharmacology Autism Network: Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361–1369, 2005
 
Riddle M: Obsessive-compulsive disorder in children and adolescents. Br J Psychiatry 173 (35 suppl):91–96, 1998
 
Riddle MA, Scahill L, King RA, et al: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31:1062–1069, 1992
[PubMed]
 
Riddle MA, Bernstein GA, Cook EH, et al: Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry 38:546–556, 1999
[PubMed]
 
Riddle MA, Reeve EA, Yaryura-Tobias JA, et al: Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40:222–229, 2001
[PubMed]
 
Rifkin A, Karajgi B, Dicker R, et al: Lithium treatment of conduct disorders in adolescents. Am J Psychiatry 154:554–555, 1997
[PubMed]
 
Ritvo ER, Freeman BJ, Geller E, et al: Effects of fenfluramine on 14 outpatients with the syndrome of autism. J Am Acad Child Psychiatry 22:549–558, 1983
[PubMed]
 
Ritvo ER, Freeman BJ, Yuwiler A, et al: Study of fenfluramine in outpatients with the syndrome of autism. J Pediatr 105:823–828, 1984
[PubMed]
 
Ritvo ER, Freeman BJ, Yuwiler A, et al: Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull 22:133–140, 1986
[PubMed]
 
Robb AS, Auby P, Nyilas M, et al: Efficacy of aripiprazole in the treatment of adolescents with schizophrenia. New research poster presented at the 160th Annual Meeting of the American Psychiatric Association, San Diego, CA, May 19–24, 2007
 
Roberts W, Weaver L, Brian J, et al: Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics 107:e71, 2001
 
Roblek T, Piacentini J: Cognitive-behavior therapy for childhood anxiety disorders. Child Adolesc Psychiatric Clin N Am 14:863–876, 2005
[PubMed]
 
Ross DC, Piggott LR: Clonazepam for OCD. J Am Acad Child Adolesc Psychiatry 32:470–471, 1993
[PubMed]
 
Ross DL, Klykylo WM, Hitzemann R: Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. Pediatr Neurol 3:83–86, 1987
[PubMed]
 
Rowland AS, Umbach DM, Stallone L, et al: Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health 92:231–234, 2002
[PubMed]
 
Rugino TA, Janvier YM: Aripiprazole in children and adolescents: clinical experience. J Child Neurol 20:603–610, 2005
[PubMed]
 
Ryan ND, Puig-Antich J, Rabinovich H, et al: MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 27:755–758, 1988
[PubMed]
 
Rynn MA, Siqueland L, Rickels K: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 158:2008–2014, 2001
[PubMed]
 
Rynn MA, Findling RL, Emslie GJ, et al: Efficacy and safety of nefazodone in adolescents with MDD. Poster presented at the 155th annual meeting of the American Psychiatric Association, Philadelphia, PA, May 18–23, 2002
 
Rynn M, Wagner KD, Donnelly C, et al: Long-term sertraline treatment of children and adolescents with major depressive disorder. J Child Adolescent Psychopharmacol 16:103–113, 2006
[PubMed]
 
Safer D, Zito JM, Fine EM: Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 98:1084–1088, 1996
[PubMed]
 
Sallee FR, Nesbitt L, Jackson C, et al: Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 154:1057–1062, 1997
[PubMed]
 
Sallee FR, Kurlan R, Goetz CG, et al: Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292–299, 2000
[PubMed]
 
Sallee FR, Miceli JJ, Tensfeldt T, et al: Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:720–728, 2006
[PubMed]
 
Sanberg PR, McConville BJ, Fogelson HM, et al: Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed Pharmacother 43:19–23, 1989
[PubMed]
 
Sanberg PR, Shytle RD, Silver AA: Treatment of Tourette's syndrome with mecamylamine. Lancet 352:705–706, 1998
[PubMed]
 
Sandler AD, Sutton KA, DeWeese J, et al: Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 341:1801–1806, 1999
[PubMed]
 
Sandor P, Musisi S, Moldofsky H, et al: Tourette syndrome: a follow-up study. J Clin Psychopharmacol 10:197–199, 1990
[PubMed]
 
Saxena K, Silverman MA, Chang K, et al: Baseline predictors of response to divalproex in conduct disorder. J Clin Psychiatry 66:1541–1548, 2005
[PubMed]
 
Saxena K, Howe M, Simeonova D, et al: Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder. J Child Adolesc Psychopharmacol 16:252–259, 2006
[PubMed]
 
Scahill L, Chappell PB, Kim YS, et al: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067–1074, 2001
[PubMed]
 
Scahill L, Leckman JF, Schultz RT, et al: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130–1135, 2003
[PubMed]
 
Scahill L, Blair J, Leckman JF, et al: Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. J Psychopharmacol 19:205–206, 2005
[PubMed]
 
Schur SB, Sikich L, Findling RL, et al: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. J Am Acad Child Adolesc Psychiatry 42:132–144, 2003
[PubMed]
 
Schuster CR, Lewis M, Seiden LS: Fenfluramine: neurotoxicity. Psychopharmacol Bull 22:148–151, 1986
[PubMed]
 
Scifo R, Cioni M, Nicolosi A, et al: Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone. Ann Ist Super Sanita 32:351–359, 1996
[PubMed]
 
Scott DW, Eames P: Use of sulpiride in a case of atypical autism. J Autism Dev Disord 18:144–146, 1988
[PubMed]
 
Seedat S, Lockhat R, Kaminer D, et al: An open trial of citalopram in adolescents with post-traumatic stress disorder. Int Clin Psychopharmacol 16:21–25, 2001
[PubMed]
 
Seedat S, Stein DJ, Ziervogel C, et al: Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. J Child Adolesc Psychopharmacology 12:37–46, 2002
[PubMed]
 
Shafey H: Use of lithium and flupenthixol in a patient with pervasive developmental disorder. Am J Psychiatry 143:681, 1986
[PubMed]
 
Shapiro AK, Shapiro E, Eisenkraft GJ: Treatment of Gilles de la Tourette's syndrome with clonidine and neuroleptics. Arch Gen Psychiatry 40:1235–1240, 1983
[PubMed]
 
Shapiro A, Shapiro E, Young J, et al: Gilles de la Tourette Syndrome, 2nd Edition. New York, Raven, 1988
 
Shapiro E, Shapiro AK, Fulop G, et al: Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 46:722–730, 1989
[PubMed]
 
Shaw JA, Lewis JE, Pascal S, et al: A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415–424, 2001
[PubMed]
 
Shaw P, Sporn A, Gogtay N, et al: Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721–730, 2006
[PubMed]
 
Shea S, Turgay A, Carroll A, et al: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:634–641, 2004
 
Sherman J, Factor DC, Swinson R, et al: The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord 19:533–543, 1989
[PubMed]
 
Sikich L, Hamer RM, Bashford RA, et al: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133–145, 2004
[PubMed]
 
Silva RR, Malone RP, Anderson LT, et al: Haloperidol withdrawal and weight changes in autistic children. Psychopharmacol Bull 29:287–291, 1993
[PubMed]
 
Silver AA, Shytle RD, Philipp MK, et al: Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 35:1631–1636, 1996
[PubMed]
 
Silver AA, Shytle RD, Philipp MK, et al: Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J Clin Psychiatry 62:707–714, 2001a
 
Silver AA, Shytle RD, Sheehan KH, et al: Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder. J Am Acad Child Adolesc Psychiatry 40:1103–1110, 2001b
 
Simeon JG: Use of anxiolytics in children. Encephale 19:71–74, 1993
[PubMed]
 
Simeon JG, Ferguson HB: Alprazolam effects in children with anxiety disorders. Can J Psychiatry 32:570–574, 1987
[PubMed]
 
Simeon JG, Ferguson HB, Van-Wyck-Fleet J: Bupropion effects in attention deficit and conduct disorders. Can J Psychiatry 31:581–585, 1986
[PubMed]
 
Simeon JG, Ferguson HB, Knott V, et al: Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 31:29–33, 1992
[PubMed]
 
Simon GE, Savarino J, Operskalski B, et al: Suicide risk during antidepressant treatment. Am J Psychiatry 163:41–47, 2006
[PubMed]
 
Simpson RL: The effects of an antipsychotic medication on the classroom behavior of four schizophrenic male children. J Autism Child Schizophr 7:349–358, 1977
[PubMed]
 
Singer HS, Brown J, Quaskey S, et al: The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double blind placebo controlled study with clonidine and desipramine. Pediatrics 95:74–81, 1995
[PubMed]
 
Snead RW, Boon F, Presberg J: Paroxetine for self-injurious behavior. J Am Acad Child Adolesc Psychiatry 33:909–910, 1994
[PubMed]
 
Snyder R, Turgay A, Aman M, et al: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026–1036, 2002
[PubMed]
 
Søndergård L, Kvist K, Andersen PK, et al: Do antidepressants precipitate youth suicide? A nationwide pharmacoepidemiological study. Eur Child Adolesc Psychiatry 15:232–240, 2006
[PubMed]
 
Spencer EK, Kafantaris V, Padron-Gayol MV, et al: Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 28:183–186, 1992
[PubMed]
 
Spencer T, Biederman J, Steingard R, et al: Nortriptyline treatment of children with attention deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 32:205–210, 1993
[PubMed]
 
Spencer T, Biederman J, Coffey B, et al: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 59:649–656, 2002
[PubMed]
 
Spencer TJ, Abikoff HB, Connor DF, et al: Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther 28:402–418, 2006a
 
Spencer TJ, Wilens TE, Biederman J, et al: Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:266–279, 2006b
 
Staller JA, Staller JA: Intramuscular ziprasidone in youth: a retrospective chart review. J Child Adolesc Psychopharmacol 14:590–592, 2004
[PubMed]
 
Stein MB, Fuetsch M, Muller N, et al: Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch Gen Psychiatry 58:251–256, 2001
[PubMed]
 
Steiner H, Petersen ML, Saxena K, et al: Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. J Clin Psychiatry 64:1183–1191, 2003
[PubMed]
 
Steingard R, Biederman J: Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. J Am Acad Child Adolesc Psychiatry 26:932–935, 1987
[PubMed]
 
Steingard RJ, Zimnitzky B, DeMaso RD, et al: Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 7:9–15, 1997
[PubMed]
 
Stephens RJ, Bassel C, Sandor P, et al: Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome—a pilot study. J Child Adolesc Psychopharmacol 14:255–266, 2004
[PubMed]
 
Stern LM, Walker MK, Sawyer MG, et al: A controlled crossover trial of fenfluramine in autism. J Child Psychol Psychiatry 31:569–585, 1990
[PubMed]
 
Storch EA, Lehmkuhl H, Geffken GR, et al: Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 25:172–174, 2008
[PubMed]
 
Stubbs EG, Budden SS, Jackson RH, et al: Effects of fenfluramine on eight outpatients with the syndrome of autism. Dev Med Child Neurol 28:229–235, 1986
[PubMed]
 
Sumner CS, Donnelly C, Lopez FA, et al: Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety. Presented at the annual meeting of the American Psychiatric Association, Atlanta, GA, May 2005
 
Sverd J: Imipramine treatment of panic disorder in a boy with Tourette's syndrome. J Clin Psychiatry 49:31–32, 1988
[PubMed]
 
Swanson JM, Flockhart D, Udrea D, et al: Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolesc Psychopharmacol 5:301–304, 1995
 
Swanson JM, Wigal SB, Udrea D, et al: Evaluation of individual subjects in the analog classroom setting, I: examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate. Psychopharmacol Bull 34:825–832, 1998
[PubMed]
 
Swanson J, Gupta S, Guinta D, et al: Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66:295–305, 1999
[PubMed]
 
Swanson J, Greenhill L, Pelham W, et al: Initiating Concerta (OROS methylphenidate HCl) qd in children with attention-deficit hyperactivity disorder. J Clin Res 3:59–76, 2000
 
Swanson JM, Gupta S, Williams L, et al: Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 41:1306–1314, 2002
[PubMed]
 
Swanson J, Gupta S, Lam A, et al: Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60:204–211, 2003
[PubMed]
 
Swanson JM, Wigal SB, Wigal T, et al: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113:e206–e216, 2004
 
Swanson JM, Greenhill LL, Lopez FA, et al: Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 67:137–147, 2006a
 
Swanson JM, Greenhill LL, Wigal T, et al: Stimulant-related reduction of growth rates in the preschool ADHD treatment study (PATS). J Am Acad Child Adolesc Psychiatry 45:1304–1313, 2006b
 
Swope GS, Hoopes SP, Amy LS, et al: An open-label study of lamotrigine in adolescents with bipolar mood disorder. New research poster presented at the 157th annual meeting of the American Psychiatric Association, New York, May 1–6, 2004
 
Tancer NK, Klein RG, Koplewicz HS, et al: Rate of atypical depression and tricyclic drug response in adolescents. J Am Acad Child Adolesc Psychiatry 31:576, 1992
 
Tanguay PE: Pervasive developmental disorders: a 10-year review. J Am Acad Child Adolesc Psychiatry 39:1079–1095, 2000
[PubMed]
 
Tannock R, Ickowicz A, Schachar R: Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 34:886–896, 1995
[PubMed]
 
Thomsen PH: Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 7:157–166, 1997
[PubMed]
 
Thomsen PH: Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series. Ann Clin Psychiatry 16:201–207, 2004
[PubMed]
 
Thomsen PH, Ebbesen C, Persson C: Long-term experience with citalopram in the treatment of adolescent OCD. J Am Acad Child Adolesc Psychiatry 40:895–902, 2001
[PubMed]
 
Todd RD: Fluoxetine in autism. Am J Psychiatry 148:1089, 1991
[PubMed]
 
Tohen M, Kryzhanovskaya L, Carlson G, et al: Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164:1547–1556, 2007
[PubMed]
 
Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527–536, 2002
 
Treatment for Adolescents with Depression Study (TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. TADS randomized controlled trial. JAMA 292:807–820, 2004
 
Troost PW, Lahuis BE, Steenhuis MP, et al: Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44:1137–1144, 2005
[PubMed]
 
Turgay A, Binder C, Snyder R, et al: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002
 
U.S. Food and Drug Administration: FDA, Final Rule, Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients, 63 Fed. Reg. 66,631 (1998); see also 21 CFR §201.23 (1999); 21 CFR §314.55 (1999); 21 CFR §601.27 (1999)
 
U.S. Food and Drug Administration: FDA News: FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medication. October 15, 2004a. Available at: http://www.fda.gov/bbs/topics/news/2004/NEW01124.html. Accessed December 2008.
 
U.S. Food and Drug Administration: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and Pediatric Advisory Committee. September 13–14, 2004b. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1.htm. Accessed December 2008.
 
U.S. Food and Drug Administration: FDA Alert [09/05]: Suicidal thinking in children and adolescents. Available at: Food and Drug Administration Website, 2005
 
U.S. Food and Drug Administration: New warning for Strattera. Available at: Food and Drug Administration Website, 2006a
 
U.S. Food and Drug Administration: Pediatric advisory committee briefing information (March 22, 2006). Available at: Food and Drug Administration Website, 2006b
 
U.S. Food and Drug Administration: Psychopharmacological drugs advisory committee briefing information (March 23, 2006). Available at: Food and Drug Administration Website, 2006c
 
U.S. Food and Drug Administration: FDA News: FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications. May 2, 2007. Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html. Accessed December 2008.
 
Valicenti-McDermott MR, Demb H: Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 16:549–560, 2006
[PubMed]
 
Varley CK, Holm VA: A two-year follow-up of autistic children treated with fenfluramine. J Am Acad Child Adolesc Psychiatry 29:137–140, 1990
[PubMed]
 
Vetro A, Szentistvanyi I, Pallag L, et al: Therapeutic experience with lithium in childhood aggressivity. Neuropsychobiology 14:121–127, 1985
[PubMed]
 
Villalaba L: Follow-up review of AERS search identifying cases of sudden death occurring with drugs used for the treatment of attention deficit hyperactivity disorder (ADHD). Available at: Food and Drug Administration Website, 2006
 
Vitiello B: Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics 108:983–989, 2001
[PubMed]
 
Volkmar F, Cook EH Jr, Pomeroy J, et al: Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 38 (12 suppl):32S–54S, 1999
 
Wagner KD, Weller E, Carlson G, et al: An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 41:1224–1230, 2002
[PubMed]
 
Wagner KD, Ambrosini P, Rynn M, et al: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 290:1033–1041, 2003a
 
Wagner KD, Cook Eh, Chung H, et al: Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 13 (suppl 1):S53–S60, 2003b
 
Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61:1153–1162, 2004a
 
Wagner, KD, Robb AS, Findling RL, et al: A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents: Am J Psychiatry 161:1079–1083, 2004b
 
Wagner KD, Jonas J, Findling RL, et al: A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45:280–288, 2006a
 
Wagner KD, Kowatch RA, Emslie GJ, et al: A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 163:1179–1186, 2006b
 
Waizer J, Polizos P, Hoffman SP, et al: A single-blind evaluation of thiothixene with outpatient schizophrenic children. J Autism Child Schizophr 2:378–386, 1972
[PubMed]
 
Walkup JT, Reeve E, Yaryura-Tobias J, et al: Fluvoxamine for childhood OCD: long-term treatment. Poster presented at the 45th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, CA, October 27–November 1, 1998
 
Weisler RH, Biederman J, Spencer TJ, et al: Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 11:625–639, 2006
[PubMed]
 
Weiss G, Hechtman L: Hyperactive Children Grown Up, 2nd Edition. New York, Guilford, 2003
 
Wigal SB, Sanchez DY, Decroy DY, et al: Selection of the optimal dose ratio for a controlled-delivery formulation of methylphenidate. J Appl Res 3:46–63, 2003
 
Wigal S, McGough J, Abikoff HB, et al: Behavioral effects of methylphenidate transdermal system in children with ADHD. Presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, CA, October 18–23, 2005a
 
Wigal SB, McGough JJ, McCracken JT, et al: A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 9:275–289, 2005b
 
Wigal T, Greenhill LL, Chuang S, et al: Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 45:1294–1303, 2006
[PubMed]
 
Wilens TE, Faraone SV, Biederman J, et al: Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179–185, 2003a
 
Wilens T, Pelham W, Stein M, et al: ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424–433, 2003b
 
Wilens T, McBurnett K, Stein M, et al: ADHD treatment with once daily OROS methylphenidate treatment: final results from a long term open-label study. J Am Acad Child Adolesc Psychiatry 44:1015–1023, 2005
[PubMed]
 
Wilens TE, McBurnett K, Bukstein O, et al: Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160:82–90, 2006a
 
Wilens TE, Newcorn JH, Kratochvil CJ, et al: Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 149:112–119, 2006b
 
Willemsen-Swinkels SH, Buitelaar JK, Weijen FG, et al: Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 58:203–215, 1995
[PubMed]
 
Willemsen-Swinkels SH, Buitelaar JK, van Engeland H: The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo controlled crossover study. Biol Psychiatry 39:1023–1031, 1996
[PubMed]
 
Willemsen-Swinkels SH, Buitelaar JK, van Berckelaer-Onnes IA, et al: Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design. J Autism Dev Disord 29:167–169, 1999
[PubMed]
 
Williams DT, Mehl R, Yudofsky S, et al: The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. J Am Acad Child Psychiatry 21:129–135, 1982
[PubMed]
 
Wolpert A, Hagamen MB, Merlis S: A comparative study of thiothixene and trifluoperazine in childhood schizophrenia. Curr Ther Res Clin Exp 9:482–485, 1967
[PubMed]
 
Wolraich ML: Evaluation of efficacy and safety or OROS methylphenidate HCI (MPH) extended release tablets, methylphenidate tid, and placebo in children with ADHD. Pediatr Res 47:36A, 2000
 
Wolraich ML, Greenhill LL, Pelham W, et al: Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108:883–892, 2001
[PubMed]
 
Wray JA, Yoon JH, Vollmer T, et al: Pilot study of the behavioral effects of flumazenil in two children with autism. J Autism Dev Disord 30:619–620, 2000
[PubMed]
 
Wright HH, Cuccaro ML, Leonhardt TV, et al: Case study: fluoxetine in the multimodal treatment of a preschool child with selective mutism. J Am Acad Child Adolesc Psychiatry 34:857–862, 1995
[PubMed]
 
Yarbrough E, Santat U, Perel I, et al: Effects of fenfluramine on autistic individuals residing in a state developmental center. J Autism Dev Disord 17:303–314, 1987
[PubMed]
 
Yoo HK, Kim JY, Kim CY: A pilot study of aripiprazole in children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 16:505–506, 2006
[PubMed]
 
Young RC, Biggs JT, Ziegler VE, et al: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435, 1978
[PubMed]
 
Zito JM, Safer DJ, dosReis S, et al: Trends in the prescribing of psychotropic medications in preschoolers. JAMA 283:1025–1030, 2000
[PubMed]
 
Zohar AH: The epidemiology of obsessive-compulsive disorder in children and adolescents. Child Adolesc Psychiatr Clin N Am 8:445–460, 1999
[PubMed]
 
Zuddas A, Ledda MG, Fratta A, et al: Clinical effects of clozapine on autistic disorder. Am J Psychiatry 153:738, 1996
[PubMed]
 
Zwier KJ, Rao U: Buspirone use in an adolescent with social phobia and mixed personality. J Am Acad Child Adolesc Psychiatry 33:1007–1011, 1994
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Which of the following medications has been approved by the U.S. Food and Drug Administration (FDA) to treat major depression in children?
2.
According to treatment guidelines developed by expert consensus and review of the available treatment literature, all of the following are recommended first-line agents for children and adolescents with bipolar I disorder except
3.
For treatment of obsessive-compulsive disorder (OCD) in children, which of the following medications is generally considered to be a third-line option, either as monotherapy or augmentation?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 11.  >
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 14.  >
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 25.  >
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 31.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation